鞘内吗啡用于下肢关节置换术后镇痛的有效性与安全性:系统评价、Meta分析及试验序贯分析
鞘内吗啡显著降低术后8-12小时静息疼痛评分,不增加呼吸抑制风险,但增加术后恶心呕吐发生率;100 µg为镇痛天花板剂量及恶心呕吐增加阈值剂量。
要点
- 鞘内吗啡显著降低关节置换术后8-12小时静息疼痛评分,且不增加呼吸抑制风险。
- 鞘内吗啡增加术后24小时内恶心呕吐发生率,但100 µg剂量时与对照组相似。
- 100 µg为鞘内吗啡的镇痛天花板剂量及恶心呕吐增加的阈值剂量。
核心结论
- 鞘内吗啡可为下肢关节置换术后提供有效镇痛,不增加呼吸抑制风险,但增加术后恶心呕吐发生率。
- 100 µg为镇痛天花板剂量及术后恶心呕吐增加的阈值剂量。
研究设计与样本
- 系统评价、Meta分析及试验序贯分析,检索比较脊髓麻醉下髋或膝关节置换术中鞘内吗啡与对照组的试验。
主要发现
- 术后8-12小时静息疼痛评分(0-10)在鞘内吗啡组显著降低,均数差(95%CI)为-1.7(-2.0至-1.3),p < 0.0001(19项试验;1420例患者;高质量证据),不同剂量间无亚组差异(p = 0.35)。
- 鞘内吗啡增加术后恶心呕吐,风险比(95%CI)为1.4(1.3-1.6),p < 0.0001(24项试验;1603例患者;高质量证据);按剂量亚组分析显示100 µg时两组术后24小时内恶心呕吐发生率相似,更大剂量时风险显著增加(亚组差异p = 0.02)。
- 接受鞘内吗啡的患者呼吸抑制风险未增加,风险比(95%CI)为0.9(0.5-1.7),p = 0.78(16项试验;1173例患者;高质量证据)。
关键数值与推荐
- 术后8-12小时静息疼痛评分均数差(95%CI)为-1.7(-2.0至-1.3),p < 0.0001,高质量证据。
- 术后恶心呕吐风险比(95%CI)为1.4(1.3-1.6),p < 0.0001,高质量证据;100 µg剂量时与对照组相似,更大剂量风险显著增加(亚组差异p = 0.02)。
- 呼吸抑制风险比(95%CI)为0.9(0.5-1.7),p = 0.78,高质量证据。
- 100 µg为镇痛天花板剂量及术后恶心呕吐增加阈值剂量。
临床怎么用
- 脊髓麻醉下髋或膝关节置换术可考虑使用鞘内吗啡改善术后镇痛,但需关注恶心呕吐。
- 选择100 µg剂量可在维持镇痛效果的同时避免增加术后恶心呕吐风险。
- 使用鞘内吗啡时呼吸抑制风险未见增加,但仍需常规监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Widespread adoption of intrathecal morphine into clinical practice is hampered by concerns about its potential side-effects. We undertook a systematic review, meta-analysis and trial sequential analysis with the primary objective of determining the efficacy and safety of intrathecal morphine. Our secondary objective was to determine the dose associated with greatest efficacy and safety. We also assessed the impact of intrathecal morphine on respiratory depression. We systematically searched the literature for trials comparing intrathecal morphine with a control group in patients undergoing hip or knee arthroplasty under spinal anaesthesia. Our primary efficacy outcome was rest pain score (0-10) at 8-12 hours; our primary safety outcome was the rate of postoperative nausea and vomiting within 24 hours. Twenty-nine trials including 1814 patients were identified. Rest pain score at 8-12 hours was significantly reduced in the intrathecal morphine group, with a mean difference (95%CI) of -1.7 (-2.0 to -1.3), p < 0.0001 (19 trials; 1420 patients; high-quality evidence), without sub-group differences between doses (p = 0.35). Intrathecal morphine increased postoperative nausea and vomiting, with a risk ratio (95%CI) of 1.4 (1.3-1.6), p < 0.0001 (24 trials; 1603 patients; high-quality evidence). However, a sub-group analysis by dose revealed that rates of postoperative nausea and vomiting within 24 hours were similar between groups at a dose of 100 µg, while the risk significantly increased with larger doses (p value for sub-group difference = 0.02). Patients receiving intrathecal morphine were no more likely to have respiratory depression, the risk ratio (95%CI) being 0.9 (0.5-1.7), p = 0.78 (16 trials; 1173 patients; high-quality evidence). In conclusion, there is good evidence that intrathecal morphine provides effective analgesia after lower limb arthroplasty, without an increased risk of respiratory depression, but at the expense of an increased rate of postoperative nausea and vomiting. A dose of 100 µg is a 'ceiling' dose for analgesia and a threshold dose for increased rate of postoperative nausea and vomiting.
引用
- Gonvers E, El-Boghdadly K, Grape S, et al. Efficacy and safety of intrathecal morphine for analgesia after lower joint arthroplasty: a systematic review and meta-analysis with meta-regression and trial sequential analysis. Anaesthesia. 2021. PMID: 34448492. doi:10.1111/anae.15569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。